VRTX

Vertex Pharmaceuticals
D

VRTX

Arincen81/100B
547.03
USD
4.03
(0.74%)
Pre Open·549.72USD+2.69(+0.49%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate 4.23Revenue estimate 3.50B
OverviewFinancialsForecastEarningsCompany

Vertex Pharmaceuticals revenue 1990–2026

Vertex Pharmaceuticals's revenue in Q3 FY2026, the three months to 30 September 2026, was 3.44B USD, up 11.8% on the same quarter a year before. Vertex Pharmaceuticals's revenue over the last twelve months was 12.99B USD, up 10.8% on the twelve months before. In fiscal year 2025 it was 12.07B USD, up 9.6% on the year before.

Last updated 9 Nov 2026 · Next report 11 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202612.99B+10.79%11.11B3.98B
FY202531 Dec 202512.07B+9.57%10.27B3.95B
FY202431 Dec 202411.02B+11.66%9.49B-535.60M
FY202331 Dec 20239.87B+10.51%8.61B3.62B
FY202231 Dec 20228.93B+17.91%7.85B3.32B
FY202131 Dec 20217.57B+22.06%6.67B2.34B
FY202031 Dec 20206.21B+49.07%5.47B2.71B
FY201931 Dec 20194.16B+36.59%3.62B1.18B
FY201831 Dec 20183.05B+22.46%2.64B2.10B
FY201731 Dec 20172.49B+46.20%2.21B263.48M
FY201631 Dec 20161.70B+64.89%1.49B-112.05M
FY201531 Dec 20151.03B+77.86%906.79M-558.12M
FY201431 Dec 2014580.42M-52.11%519.43M-738.56M
FY201331 Dec 20131.21B-20.63%1.08B-445.03M
FY201231 Dec 20121.53B+8.25%1.25B-107.03M
FY201131 Dec 20111.41B+883.91%1.33B29.57M
FY201031 Dec 2010143.37M+40.49%130.64M-754.63M
FY200931 Dec 2009102.05M-41.85%87.85M-641.58M
FY200831 Dec 2008175.50M-11.81%159.82M-459.85M
FY200731 Dec 2007199.01M-8.02%185.11M-391.28M
FY200631 Dec 2006216.36M+34.47%204.19M-206.89M
FY200531 Dec 2005160.89M+56.63%150.79M-203.42M
FY200431 Dec 2004102.72M+48.56%97.07M-166.25M
FY200331 Dec 200369.14M-57.08%66.02M-196.77M
FY200231 Dec 2002161.09M-3.82%132.80M-108.62M
FY200131 Dec 2001167.49M+114.38%127.86M-66.23M
FY200031 Dec 200078.13M+26.83%74.05M-39.66M
FY199931 Dec 199961.60M+38.74%65.00M-41.00M
FY199831 Dec 199844.40M+1.37%48.90M-33.10M
FY199731 Dec 199743.80M+229.32%47.40M-19.80M
FY199631 Dec 199613.30M-39.82%16.50M-40.00M
FY199531 Dec 199522.10M+12.76%25.80M-21.50M
FY199431 Dec 199419.60M-29.75%23.10M-17.60M
FY199331 Dec 199327.90M+634.21%31.80M2.00M
FY199231 Dec 19923.80M+18.75%6.60M-8.50M
FY199131 Dec 19913.20M+39.13%5.00M-5.10M
FY199031 Dec 19902.30M—2.30M-4.30M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Vertex Pharmaceuticals revenue growth by segment

Q3 FY2026 against Q3 FY2025

TRIKAFTA/KAFTRIO2.44B
-8.2%
ALYFTREK705.80M
+185.7%
Manufactured Product, Other130.50M
-25.8%

Vertex Pharmaceuticals revenue by segment over time

TRIKAFTA/KAFTRIO ALYFTREK Manufactured Product, Other INCIVEK ORKAMBI KALYDECO SYMDEKO/SYMKEVI
Fiscal yearTRIKAFTA/KAFTRIOALYFTREKManufactured Product, OtherINCIVEKORKAMBIKALYDECOSYMDEKO/SYMKEVI
FY202510.31B +0.7%837.80M 820.10M +4.9%— — — —
FY202410.24B +14.5%— 781.50M — — — —
FY20238.94B +16.4%— — — 326.00M -36.2%475.50M -14.0%123.00M -31.7%
FY20227.69B +34.9%— — — 510.70M -33.8%553.20M -19.1%180.00M -57.2%
FY20215.70B +47.4%— — — 771.60M -15.0%684.20M -14.8%420.40M -33.1%
FY20203.86B +819.7%— — — 907.51M -31.9%802.87M -19.0%628.58M -55.7%
FY2019420.11M — — — 1.33B +5.5%991.06M -1.6%1.42B +84.4%
FY2018— — — 0.00 1.26B -4.4%1.01B +19.3%768.66M
FY2017— — — 0.00 -100.0%1.32B +34.8%844.63M +20.1%—
FY2016— — — 610.00K -96.6%979.59M +179.4%703.43M +11.4%—

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Vertex Pharmaceuticals's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.